Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
DATA GRAPHICS | Finance

IPO superstars

Back to School 2023: Six companies with NASDAQ IPOs since 2021 have more than doubled their market caps. Another four met the doubling mark via M&A

August 30, 2023 5:23 PM UTC

Six biopharma companies pricing IPOs on NASDAQ between the start of 2021 and the end of 1H23 have already seen their market capitalizations more than double, out of more than 154 IPOs on U.S. markets in that time. Four more have been acquired at prices more than twice their postmoney valuations.

The analysis sits alongside the Back to School 2023 essay, which focuses on building sustainable high-value biotechs, breaks down the landscape of public biotechs by market cap tier, and examines the criteria for jumping tier (see “Tier-jumpers: Building the road to sustainable biotechs”)...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article